Calliditas Therapeutics has launched an investor roadshow for a contemplated initial public offering of American Depositary Shares in the United States for trading on The Nasdaq Global Market in the United States and a concurrent private placement of common shares to certain qualified investors in Europe and other countries outside of the United States.
The target size of the global offering is MUSD 75 of gross proceeds plus a potential over-allotment of 15 percent.
The filing of the preliminary prospectus in the United States with the SEC has no implications for Calliditas’ listing on Nasdaq Stockholm in Sweden.
Photo of Renee Aguiar-Lucander: CEO, Calliditas
